Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
The two companies are collaborating on Field Trip at Home Powered by Nue Life, a partnership that provides ketamine treatments from the comfort of a person’s home.Through this arrangement, Field Trip now offers increased accessibility and convenience for those interested in pursuing the powerful treatment outcomes of ketamine therapy outside of a clinic setting through Nue Life’s at-home and telehealth offerings.
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments.
Microdose was at the PSYCH Symposium in London last week and the anticipation for these results was palpable. The industry has been waiting for a shot of good news.
“We are encouraged by the positive data showing that LSD produced rapid, strong and long-lasting reductions in anxiety and depression symptoms up to 16 weeks post treatment compared with a placebo,” said Dr. Miri Halperin Wernli, Executive President of MindMed.
The double-blind, randomised, placebo-controlled study (“PSILAUT”) will investigate whether there is a difference in the function of serotonin brain networks in autistic and non-autistic adults. The researchers will use a range of imaging techniques and behavioural tasks to examine how the serotonin system is modulated by COMP360 psilocybin.
“This pre-IND meeting continues our diligent work towards initiating the clinical trial with CMND-100 by the end of 2022, which is of foremost importance to Clearmind in its aim to be a leader in developing psycho-targeted pharmaceuticals,” said Zuloff-Shani.
Clearmind’s lead product, CMND-100, is a novel psychedelic-derived drug candidate, exerting a significant reduced desire to consume alcoholic beverages.